| abstract |
The present invention relates to a pharmaceutical composition comprising the compound suborexant or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer and optionally a pharmaceutically acceptable surfactant. The concentration-enhancing polymer, in combination with suborexant, which is insoluble in water or almost completely insoluble in water, (a) dissolves suborexant or (b) prevents suborexant from forming crystalline or crystalline domains in the polymer. It is a polymer that forms an amorphous dispersion by interacting with suborexant. Concentration-enhancing polymers are water-soluble or readily dispersible in water, whereby the solubility and/or bioavailability of suborexant is polymer when the polymer is placed in a water or aqueous environment (such as gastrointestinal (GI) duct or artificial GI fluid) Solubility in the absence or bioavailability increases. |